DEVELOPMENT OF NOVEL CYCLOSPROINE OPHTHALMIC EMULSION FORMULATIONS FOR TREATING DRY EYE DISORDER

Kamini Kashyap, Basudha Singh Gautam* and Satish Sahu

ABSTRACT

Dry eye is a multifactorial disorder of the ocular surface involving the tear film and the reflex control of tear homeostasis. There are two major forms of dry eye: lacrimal-deficient or aqueous-deficient dry eye (ADDE) and evaporative dry eye (EDE). In the United States and worldwide, dry eye has been estimated to affect 5–30% of the population. Patients with dry eye complain of a variety of symptoms including poor visual quality, pain (burning, aching) and tearing. Symptoms associated with dry eye are a leading cause of visits to eye clinics and its treatment has significant cost implications. Dry eye adversely impacts quality of life as its symptoms interfere with activities of daily living such as driving, reading and watching television. Studies using the Impact of Dry Eye on Everyday Life questionnaire have confirmed that dry eye negatively affects physical and mental functioning.[1]

Keywords: .